INT22272

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1990
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 28
Total Number 30
Disease Relevance 7.62
Pain Relevance 13.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell death (HTR2A) aging (HTR2A) plasma membrane (HTR2A)
response to stress (HTR2A) cytoplasm (HTR2A) signal transducer activity (HTR2A)
Anatomy Link Frequency
platelet 4
dentate gyrus 1
cerebral cortex 1
brain 1
M-1 1
HTR2A (Homo sapiens)
Pain Link Frequency Relevance Heat
Serotonin 74 100.00 Very High Very High Very High
antagonist 60 100.00 Very High Very High Very High
sSRI 33 100.00 Very High Very High Very High
noradrenaline 11 100.00 Very High Very High Very High
Analgesic 4 99.96 Very High Very High Very High
fluoxetine 54 99.88 Very High Very High Very High
Potency 3 98.92 Very High Very High Very High
Somatostatin 6 98.84 Very High Very High Very High
cerebral cortex 1 98.84 Very High Very High Very High
agonist 40 98.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Reprotox - General 1 29 99.24 Very High Very High Very High
Sprains And Strains 4 98.92 Very High Very High Very High
Epilepsy 10 98.18 Very High Very High Very High
Hypotension 6 98.16 Very High Very High Very High
Headache 115 98.00 Very High Very High Very High
Urological Neuroanatomy 11 97.00 Very High Very High Very High
Nociception 16 96.64 Very High Very High Very High
Depression 28 94.76 High High
Disease 12 93.96 High High
Tremor 69 91.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results were corroborated by 3H-spiperone binding to platelet membranes: in migraineurs with aura in the attack-free interval, there was a significant decrease in its Bmax, which suggests down-regulation of 5-HT2 receptors.
Negative_regulation (down-regulation) of 5-HT2 in platelet associated with epilepsy
1) Confidence 0.57 Published 1990 Journal Cephalalgia Section Abstract Doc Link 2272090 Disease Relevance 0.67 Pain Relevance 0.79
This suggests that chronic treatment by SSRIs could induce an up-regulation of the 5-HT2A receptors, and that 5-HT2A receptor down-regulation is not a common mechanism for the therapeutic effects of all serotoninergic antidepressive drugs.
Negative_regulation (down-regulation) of 5-HT2A associated with ssri
2) Confidence 0.57 Published 1997 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 9335087 Disease Relevance 0.24 Pain Relevance 0.21
The antidepressant, mianserin, is a serotonin receptor (5-HT2) antagonist and produces down-regulation of 5-HT2 and 5-HT1c receptors in the cerebral cortex of rats.
Negative_regulation (regulation) of 5-HT2 in cerebral cortex associated with antidepressant, antagonist, cerebral cortex and serotonin
3) Confidence 0.57 Published 1993 Journal Life Sci. Section Abstract Doc Link 8326822 Disease Relevance 0 Pain Relevance 0.36
In our previous study, the 5HT2A receptor mRNA was significantly reduced, whereas the 5HT2C receptor mRNA was enhanced after repeated intermittent MDMA administration [25], indicating on compensatory mechanisms in response to long term MDMA administration.
Negative_regulation (reduced) of 5HT2A
4) Confidence 0.57 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2358913 Disease Relevance 0.25 Pain Relevance 0.50
While fluoxetine also reduced 5HT2A-R function, but to a lesser degree, imipramine increased 5HT2A-R function, which may explain why mI seems to be effective exclusively in selective serotonin reuptake inhibitor-sensitive disorders.
Negative_regulation (reduced) of 5HT2A-R associated with ssri and fluoxetine
5) Confidence 0.55 Published 2004 Journal Metab Brain Dis Section Abstract Doc Link 15214506 Disease Relevance 0.29 Pain Relevance 0.60
This prospective randomized controlled study was performed to evaluate the efficacy of the 5-HT2A receptor inhibitor in the treatment of symptomatic lumbar disc herniation.
Negative_regulation (inhibitor) of 5-HT2A
6) Confidence 0.42 Published 2005 Journal Journal of neurosurgery. Spine Section Abstract Doc Link 15871484 Disease Relevance 0.09 Pain Relevance 0.14
The 5-HT2A inhibitor has the potential to alleviate symptoms in patients with lumbar disc herniation.


Negative_regulation (inhibitor) of 5-HT2A
7) Confidence 0.42 Published 2005 Journal Journal of neurosurgery. Spine Section Body Doc Link 15871484 Disease Relevance 0 Pain Relevance 0
It is metabolised to racemic M-1 and both enantiomers of M-1 are also antagonists of 5-HT2A receptors.
Negative_regulation (antagonists) of 5-HT2A in M-1 associated with antagonist
8) Confidence 0.42 Published 2004 Journal Expert Opin Investig Drugs Section Abstract Doc Link 15212624 Disease Relevance 0.95 Pain Relevance 0.16
By contrast, in rats chronically treated with analgesics, 5-HT2A receptors are down-regulated [34] and the 5-HT transporter is up-regulated in the cortex [34] and in platelets [35].
Negative_regulation (regulated) of 5-HT2A in platelets associated with analgesic
9) Confidence 0.42 Published 2010 Journal BMC Neurol Section Body Doc Link PMC3024248 Disease Relevance 0.43 Pain Relevance 1.51
Mirtazapine has a unique tolerability profile, since the specific postsynaptic 5-HT2 and 5-HT3 receptor blockade of mirtazapine provides early antidepressant effects without causing unwanted serotonin-related side-effects.
Negative_regulation (blockade) of 5-HT2 associated with antidepressant and serotonin
10) Confidence 0.42 Published 1998 Journal J Affect Disord Section Abstract Doc Link 10333982 Disease Relevance 0.55 Pain Relevance 0.41
Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine.
Negative_regulation (Exclusion) of 5-HT2A associated with migraine
11) Confidence 0.42 Published 1996 Journal Headache Section Title Doc Link 8675433 Disease Relevance 0.43 Pain Relevance 0.48
Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity.
Negative_regulation (inhibitor) of 5-HT2A associated with ssri
12) Confidence 0.42 Published 1996 Journal Neuropharmacology Section Title Doc Link 9025110 Disease Relevance 0.06 Pain Relevance 0.51
Thus, YM992, having both selective 5-HT reuptake inhibition and 5-HT2A antagonistic activity, might show potent therapeutic activity as a novel antidepressant in comparison with conventional SSRIs.
Negative_regulation (inhibition) of 5-HT2A associated with antidepressant and ssri
13) Confidence 0.42 Published 1996 Journal Neuropharmacology Section Abstract Doc Link 9025110 Disease Relevance 0.09 Pain Relevance 0.60
Nefazodone was initially discovered for its ability to block 5-HT2A receptors and its reduced potency as an alpha 1-adrenergic blocker.
Negative_regulation (block) of 5-HT2A associated with reprotox - general 1 and potency
14) Confidence 0.41 Published 1995 Journal J Clin Psychiatry Section Abstract Doc Link 7649970 Disease Relevance 0.16 Pain Relevance 0.35
We conclude that hypotensive and vasorelaxant effects of eugenosedin-B can be attributed to its multiple actions on the blockade of 5-HT1B, 5-HT2A, alpha1/2 and beta1 receptors, and its ability to reduce platelet aggregation attributed to its blockade of alpha2 and 5-HT2A receptors.
Negative_regulation (blockade) of 5-HT2A in platelet associated with hypotension
15) Confidence 0.41 Published 2008 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 18287883 Disease Relevance 0.28 Pain Relevance 0.18
Unlike other antidepressants, mirtazapine does not inhibit the reuptake of serotonin or norepinephrine but acts as an antagonist at presynaptic and, presumably, postsynaptic alpha 2-receptors as well as an antagonist of postsynaptic 5-HT2 and 5-HT3-receptors.
Negative_regulation (antagonist) of 5-HT2 associated with antidepressant, antagonist and serotonin
16) Confidence 0.41 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.14 Pain Relevance 0.23
We conclude that hypotensive and vasorelaxant effects of eugenosedin-B can be attributed to its multiple actions on the blockade of 5-HT1B, 5-HT2A, alpha1/2 and beta1 receptors, and its ability to reduce platelet aggregation attributed to its blockade of alpha2 and 5-HT2A receptors.
Negative_regulation (blockade) of 5-HT2A in platelet associated with hypotension
17) Confidence 0.41 Published 2008 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 18287883 Disease Relevance 0.17 Pain Relevance 0.17
2 presynaptic receptors and increases noradrenergic and serotoninergic transmission while blocking the 5-HT2 and 5-HT3 receptors.
Negative_regulation (blocking) of 5-HT2
18) Confidence 0.41 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671731 Disease Relevance 0.66 Pain Relevance 0.32
These experiments were designed to test whether blocking 5HT2A/2c receptors in the CA1 region of the hippocampus and dentate gyrus would decrease nociceptive behaviors induced by a peripheral noxious stimulus formalin as an animal model of unremitting human being.
Spec (whether) Negative_regulation (blocking) of 5HT2A in dentate gyrus associated with nociception and hippocampus
19) Confidence 0.41 Published 2006 Journal Behav. Brain Res. Section Abstract Doc Link 16377002 Disease Relevance 0.33 Pain Relevance 0.14
However, in contrast to fluoxetine, S 15535 elicited a significant (25%) decrease in the density (Bmax) of 5-HT2A receptors labeled by [3H]ketanserin in the cortex; there was no alteration in Kd.
Negative_regulation (decrease) of 5-HT2A in cortex associated with fluoxetine
20) Confidence 0.41 Published 1997 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 9223549 Disease Relevance 0.29 Pain Relevance 0.95

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox